21世纪经济报道记者季媛媛上海报道今年一季度，受到创新药政策支持、出海加速、BD（商务拓展）授权推动等因素的加持，不少创新药企业绩扭亏为盈，取得开门红。根据诺诚健华披露的一季度报，2025年第一季度，诺诚健华总收入同比增长129.9%，达到3.8亿元，主要归功于核心产品奥布替尼（商品名：宜诺凯®）的持续放量以及公司与Prolium达成授权许可获得的首付款。数据显示，奥布替尼当季同比增长89.2%，...
Source Link21世纪经济报道记者季媛媛上海报道今年一季度，受到创新药政策支持、出海加速、BD（商务拓展）授权推动等因素的加持，不少创新药企业绩扭亏为盈，取得开门红。根据诺诚健华披露的一季度报，2025年第一季度，诺诚健华总收入同比增长129.9%，达到3.8亿元，主要归功于核心产品奥布替尼（商品名：宜诺凯®）的持续放量以及公司与Prolium达成授权许可获得的首付款。数据显示，奥布替尼当季同比增长89.2%，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.